NCT00133900

Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy

Circulating Tumor Cells and the Prediction of Overall Survival in Patients With Androgen Independent Prostate Cancer Entering Onto Chemotherapy

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 276 (actual)
• Sponsor: Immunicon · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study enrolled men with prostate cancer who had failed hormone therapy (as shown by rising prostate-specific antigen \[PSA\] levels) and who were about to start a new line of chemotherapy. Blood was drawn prior to the patient receiving chemotherapy and then monthly thereafter for up to 18 months or until disease progression, whichever occurred first. The blood was tested to find circulating tumor cells (CTC) and to count them. The circulating tumor cell levels were studied in relation to the patient's overall survival. Serum was also collected for PSA testing, and additional blood samples were drawn to test for circulating endothelial cells and RNA was isolated for future gene expression testing.

Conditions

• Hormone Refractory Prostate Cancer
• Prostate Cancer

Interventions

Type	Name	Description
PROCEDURE	Phlebotomy	Peripheral blood draws for evaluation of circulating tumor cells

Timeline

• Start date: 2004-12-01
• Primary completion: 2009-02-01
• Completion: 2009-02-01
• First posted: 2005-08-24
• Last updated: 2009-07-28

Locations

1 site across 1 country: United States